Bendroflumethiazide: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page

Bendroflumethiazide

Thiazides, Plain

GB MHRA

Drug class: Thiazides, Plain
Availability: See label
Markets covered: 1
Products on record: 20

Overview

Bendroflumethiazide is an active pharmaceutical ingredient in the Thiazides, Plain group (C03AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	20	May 15, 2026

GBUnited Kingdom· MHRA

20 products

Uses

GBOfficial regulatory label· revised September 5, 2025[1]

Bendroflumethiazide is indicated for:
Cases where the reduction of fluid retention by diuresis is required; oedema of cardiac, renal or hepatic origin and iatrogenic oedema. Bendroflumethiazide produces a moderate but usefully prolonged fall of blood pressure in hypertensive patients.
It may be used as the sole antihypertensive agent or as an adjunct to other drugs whose action it potentiates. In non-oedematous patients, there may be little noticeable diuretic effect.

How to take

Drug interactions

Known interactions involving Bendroflumethiazide. Select one for details. This list is informational and not a complete interaction checker.

Aminolevulinic Acid Amiodarone Arsenic Trioxide Cisapride Dofetilide Dolasetron Dronedarone Droperidol Lithium Carbonate Pimozide Tizanidine Ziprasidone Acarbose Acebutolol Albiglutide Albuterol Aldesleukin Alfentanil Alfuzosin Allopurinol Alogliptin Alprazolam Amifostine Amisulpride Amitriptyline Amoxapine Amphotericin B Apomorphine Apraclonidine Arformoterol Aripiprazole Asenapine Atenolol Atracurium Avanafil Baclofen Benazepril Benzhydrocodone Betamethasone Betaxolol Bisacodyl Bisoprolol Brexpiprazole Brimonidine Bumetanide Buprenorphine Bupropion Buspirone Butabarbital Butorphanol Cabergoline Calcifediol Calcitriol Calcium Acetate Calcium Carbonate Calcium Chloride Calcium Citrate Calcium Gluconate Calcium Lactate Calcium Phosphate Canagliflozin Capecitabine Captopril Carbamazepine Cariprazine Carisoprodol Carteolol Carvedilol Castor Oil Celecoxib Chlordiazepoxide Chlorpromazine Chlorpropamide Cholecalciferol Cisatracurium Citalopram Clobazam Clomipramine Clonazepam Clorazepate Clozapine Codeine Colestipol Corticotropin Cosyntropin Cyclophosphamide Cyclosporine Dapagliflozin Deflazacort Deserpidine Desvenlafaxine Dexamethasone Dexlansoprazole Dexmedetomidine Diatrizoate Diazepam Diazoxide Diclofenac Diflunisal Digoxin Dihydrocodeine Dimenhydrinate Disopyramide Doxacurium Doxazosin Doxepin Doxercalciferol Dronabinol Dulaglutide Duloxetine Empagliflozin Enalapril Epoprostenol Ergocalciferol Ertugliflozin Escitalopram Eslicarbazepine Esomeprazole Ethacrynate Ethanol Etodolac Exenatide Fenoldopam Fenoprofen Fentanyl Fludrocortisone Fluorouracil Fluoxetine Fluphenazine Flurazepam Flurbiprofen Fluvoxamine Formoterol Fosinopril Furosemide Glimepiride Glipizide Glyburide Glycerin Guanabenz Guanfacine Haloperidol Hydrocodone Hydrocortisone Hydromorphone Hydroxyzine Ibuprofen Iloperidone Iloprost Imipramine Indacaterol Indomethacin Insulin Degludec Insulin Detemir Insulin Glargine Insulin Lispro Iohexol Iopamidol Iopromide Iothalamic Acid Ioversol Ioxilan Irinotecan Isocarboxazid Ketoprofen Ketorolac Labetalol Lactitol Lactulose Lansoprazole Levobunolol Levodopa Levomilnacipran Licorice Linagliptin Linezolid Liraglutide Lisinopril Lixisenatide Lofexidine Lorazepam Loxapine Lumateperone Lurasidone Magnesium Citrate Magnesium Hydroxide Maprotiline Maraviroc Meclofenamic Acid Mefenamate Meloxicam Meperidine Meprobamate Mesoridazine Metaproterenol Metformin Methadone Methenamine Methocarbamol Methotrexate Methoxsalen Methylprednisolone Metipranolol Metoprolol Midazolam Miglitol Milnacipran Mineral Oil Mirtazapine Mivacurium Moexipril Molindone Morphine Nabilone Nabumetone Nadolol Nalbuphine Naproxen Nateglinide Nebivolol Nefazodone Olanzapine Oliceridine Olodaterol Olopatadine Omeprazole Opium Oxaprozin Oxazepam Oxycodone Ozanimod Paliperidone Pancuronium Pantoprazole Paricalcitol Paroxetine Pentazocine Pentoxifylline Perindopril Perphenazine

Showing 240 of 341. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL537970071 · revised September 5, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised September 5, 2025[1]

Summary of safety profile The safety profile of bendroflumethiazide includes a degree of electrolyte imbalance. Serious adverse reactions include pancreatitis, hypersensitivity reactions, serious skin reactions and blood dyscrasias.
Adverse reactions listed below are based on available data for bendroflumethiazide and classified according to frequency and system organ class (SOC). Frequency categories are defined according to the following convention: very common (≥1/10), common (≥ 1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (1/10,000 to < 1/1,000), very rare (< 1/10,000), and not known (cannot be estimated from the available data).
Table 1. Adverse reactions System organ class Very common Common Uncommon Rare Very rare Not known Blood and lymphatic system disorders Blood dyscrasias, including neutropenia, agranulocytosis, aplastic anaemia, thrombocytopenia and leucopenia Immune system disorders Hypersensitivity reactions Endocrine disorders Thiazides may cause hyperglycaemia and aggregate or unmask diabetes mellitus.
Nervous system disorders Headache Dizziness Paraesthesia Drowsiness Eye disorders Choroidal effusion* Vascular disorders Postural hypotension Vasculitis Respiratory thoracic and mediastinal disorders Pneumonitis and pulmonary oedema (as part of hypersensitivity reaction) Gastrointestinal disorders Pancreatitis Nausea Vomiting Diarrhoea Constipation Gastric Irritation Dry Mouth Thirst Hepatobiliary disorders Cholestasis Cholecystitis Skin and subcutaneous tissue disorders Rashes (including exfoliative dermatitis) Photosensitivity Skin eruptions resembling lichen planus and subacute cutaneous lupus erythematosus Erythema multiforme Pseudoporphyria Musculoskeletal and connective tissue disorders Systemic lupus erythematosus Renal and urinary disorders Acute interstitial nephritis Non-opaque urate calculi Oliguria Reproductive system and breast disorders Impotence (reversible on discontinuing the drug) Investigations Increased triglyceride, total cholesterol, low- density and very- low density lipoprotein cholesterol concentrations Hypokalaemia.
Hypomagnesaemia Hyponatraemia Hypercalcaemia Hypochloraemic alkalosis Hyperuricaemia with/without gout *see subsection below for additional information Description of selected adverse reactions Choroidal effusion: Cases of choroidal effusion with visual field defect have been reported after the use of thiazide and thiazide-like diuretics.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised September 5, 2025[1]

Hypokalaemia Electrolytes should be monitored during treatment as continued or intensive use of bendroflumethiazide may result in hypokalaemia. This effect may be enhanced with concomitant use of medicines that can also cause hypokalaemia.
This effect may be enhanced with concomitant use of medicines that can also cause hypokalaemia such as other diuretics or beta-2 agonists. 5). Potassium replacement or conservation may be necessary in patients at risk from the cardiac effects of hypokalaemia, such as those with prolonged QT intervals, severe heart disease, those taking digitalis preparations or high doses of diuretics and in patients with severe liver disease.
4 mmol potassium) is detected, it must be corrected and it should be prevented in at-risk patients. Potassium supplements should not be given in renal insufficiency complicated by hyperkalaemia. Potassium supplementation alone may not be sufficient to correct hypokalaemia in patients who are also deficient in magnesium.
Hyponatraemia Some patients may be particularly susceptible to hyponatraemia, including the elderly and those with severe heart failure who are very oedematous, particularly with large doses of thiazides in conjunction with restricted salt in the diet.
The onset of hyponatraemia can be sudden and life-threatening. All patients, including the elderly who may be particularly susceptible, should be carefully observed for signs of fluid and electrolyte imbalance, especially in the presence of vomiting or during parenteral fluid therapy.
Regular serum electrolyte determinations should be performed in the elderly and in patients receiving long-term therapy. Hypomagnesaemia There is an increased risk of hypomagnesaemia in patients with alcoholic cirrhosis taking Bendroflumethiazide.
Hypomagnesaemia has been implicated as a risk factor for arrhythmias. Electrolyte levels including magnesium should be monitored during treatment of patients with alcoholic cirrhosis. Hypercalcaemia Thiazides may decrease urinary calcium excretion and may cause intermittent and slight elevation of serum calcium.
Marked hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function. Choroidal effusion, acute myopia and secondary angle-closure glaucoma Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations